Beijing Tide Out-Licenses Ex-China Rights to Fibrosis Therapy in $518 Million Deal
March 17, 2021 at 07:14 AM EDT
Beijing Tide Pharma. a subsidiary of Sino Biopharmaceutical, out-licensed ex-China rights for a fibrosis therapy to Graviton Bio of New York in a deal worth up to $517.5 million. TDI01 is a targeted inhibitor of Rho/Rho containing protein kinase 2 (ROCK2). In 2020, the candidate was approved to start Phase I clinical trials to treat fibrosis in China and the US . Graviton expects to expand development of TDI01 to include CNS, preclinical cancer and viral disease indications. More details.... Stock Symbol: (HK: 1177) Share this with colleagues: // //
